Lakewood-Amedex Biotherapeutics adds biotech CEO Joseph Tucker to board after Nasdaq listing

Lakewood-Amedex Biotherapeutics appointed Joseph Tucker, CEO of Enveric Biosciences, to its Board of Directors following its recent Nasdaq direct listing. Tucker brings over 20 years of biotech leadership and capital markets experience, expected to support the company's growth and development of its lead antimicrobial product, Nu-3, targeting infected diabetic foot ulcers. This move strengthens governance as Lakewood-Amedex advances clinical trials and expands its pipeline against antibiotic-resistant infections. Tucker expressed enthusiasm about contributing to the company's next growth phase and the potential impact of Nu-3 on urgent medical needs.